Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Cutaneous T-cell Lymphoma.

Statements

Source and description
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
Adcetris (brentuximab vedotin) [product information]. EMA. The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.